Olabimpe Caroline Badejogbin

Ms. Olabimpe Caroline Badejogbin

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2025 in Metabolic Brain Disease
Verified
Journal Article
Closed access
PDF file
SAStephanie E. Areloegbe
Stephanie E. Areloegbe
NONsisong N. Obong
Nsisong N. Obong
OBOlabimpe Caroline Badejogbin
Olabimpe Caroline Badejogbin
AOAdesola Adedotun Oniyide
Adesola Adedotun Oniyide
IAIsaac O. Ajadi
Isaac O. Ajadi
KOKehinde Olaniyi
Kehinde Olaniyi

26 January 2026 in BioMed Research International
Verified
Journal Article
Open access
OBOlabimpe Caroline Badejogbin
Olabimpe Caroline Badejogbin
MAMary Olaoluwa Agunloye
Mary Olaoluwa Agunloye
OCOjichukwuka Ebere Chijioke-Agu
Ojichukwuka Ebere Chijioke-Agu
MOMakinde Vincent Olubiyi
Makinde Vincent Olubiyi
SOSuccess Oluwanifesimi Olugbuyiro
Success Oluwanifesimi Olugbuyiro
TOTobi Opeyemi Olaleye
Tobi Opeyemi Olaleye
Background: Polycystic ovary syndrome (PCOS) is a common endocrine disorder that significantly increases cardiovascular disease (CVD) risk in women. While insulin resistance and dyslipidemia are established contributors, growing evidence highlights mitochondrial dysfunction and chronic low‐grade inflammation as central drivers of cardiovascular pathology in PCOS. Objective: This narrative review synthesizes current evidence on how mitochondrial dysfunction and inflammation interact to promote cardiovascular complications in women with PCOS while identifying potential therapeutic targets and areas requiring further investigation. Methods: A comprehensive review of clinical and experimental studies was conducted using PubMed, Scopus, and Web of Science databases. Relevant literature exploring mitochondrial alterations, oxidative stress, inflammatory cytokines, and endothelial function in PCOS, with emphasis on cardiovascular outcomes, was critically evaluated and summarized. Results: Women with PCOS exhibit altered mitochondrial dynamics, reduced ATP production, and elevated reactive oxygen species (ROS), which collectively impair vascular function. These mitochondrial abnormalities compromise oocyte quality and endometrial receptivity and activate proinflammatory signaling pathways, including the NLRP3 inflammasome, contributing to endothelial dysfunction and atherogenesis, and increased long‐term cardiovascular risk, particularly in women with prior pregnancy complications. Elevated levels of cytokines including TNF‐ α , IL‐6, and CRP further exacerbate cardiovascular risk. This bidirectional relationship between mitochondrial dysfunction and inflammation establishes a vicious cycle underlying cardiovascular deterioration in PCOS. Conclusion: Mitochondrial dysfunction and inflammation are interdependent mechanisms that contribute substantially to cardiovascular risk in women with PCOS. Targeting mitochondrial dysfunction and systemic inflammation presents a promising therapeutic strategy for reducing cardiovascular morbidity in PCOS. Future research should emphasize phenotype‐specific interventions, biomarker discovery, and translational trials to improve long‐term reproductive and cardiovascular outcomes.

16 November 2024 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Closed access
PDF file
KOKehinde Olaniyi
Kehinde Olaniyi
SAStephanie Esosa Joy Areloegbe
Stephanie Esosa Joy Areloegbe
OBOlabimpe Caroline Badejogbin
Olabimpe Caroline Badejogbin
IAIsaac O. Ajadi
Isaac O. Ajadi
MAMary B. Ajadi
Mary B. Ajadi

30 September 2026 in Endocrines
Verified
Journal Article
Open access
PDF file
OBOlabimpe Caroline Badejogbin
Olabimpe Caroline Badejogbin
GOGabriel O. Oludare
Gabriel O. Oludare
BIBOLANLE O. IRANLOYE
BOLANLE O. IRANLOYE
Background: Diabetes in males leads to hyperglycemia-induced oxidative stress and inflammation in the testis, resulting in apoptosis. Diabetes-induced testicular impairment has been linked to the implication with the gut–brain axis. Sodium butyrate, a product of the gut microbiota fermentation process, has been targeted for its anti-diabetic, anti-inflammatory, and antioxidative functions. This research, therefore, explored sodium butyrate as a therapeutic potential intervention in mitigating diabetes-induced testicular dysfunction. Methods: Thirty-five male rats were randomly assigned to five groups after diabetes was confirmed: healthy control (CON), sodium butyrate-treated (SBUT; 200 mg/kg orally), diabetic control (T1DM; 50 mg/kg STZ intraperitoneally), diabetes + sodium butyrate (T1DM + SBUT), and diabetes + insulin (T1DM + INSL, 0.9 I.U/100 g/day). Body weight, testicular weight, glucose homeostasis (fasting blood sugar, oral glucose tolerance, and glycated hemoglobin), lipid profile, testosterone level, sperm analysis, histopathology of the testis, and anti-apoptotic markers (B-cell lymphoma-2 (Bcl-2), Bcl-associated protein X (Bax), and Caspase-3) were all assessed. Results: Along with elevated blood glucose and glycated hemoglobin levels, diabetic rats showed a notable decrease in body weight, testicular mass, gonadosomatic index, sperm count, motility, viability, and normal morphology. Elevated Bax and Caspase-3 expression with reduced Bcl-2 were observed alongside testicular fibrosis, accumulation of collagen, and carbohydrate-rich substances. Sodium butyrate treatment, by downregulating Bax and Caspase-3 and upregulating Bcl-2, conserved testicular histoarchitecture, restored sperm quality, controlled apoptotic signaling, and markedly improved metabolic indices. Conclusions: Sodium butyrate displayed a protective role in the testis in diabetic conditions via the modulation of hyperglycemia-induced apoptosis, identifying this as a potential therapeutic intervention in diabetes-induced testicular dysfunction.